The U.S. Food and Drug Administration approved Infilbray (venglustat) on Wednesday marking the first treatment authorized for the neurological symptoms of Gaucher disease type 3.
The oral medication crosses the blood-brain barrier to inhibit glucosylceramide synthase, reducing the buildup of glucosphingolipids in the brain and other organs. The approval covers adults and pediatric patients weighing at least 15 kilograms (about 33 pounds), the FDA announced.
Acting FDA Commissioner Kyle Diamantas said the drug’s ability to reach the central nervous system addresses the progressive motor and cognitive decline that distinguishes type 3 from type 1 Gaucher disease. Patients with type 3 experience worsening balance, coordination, speech, memory and thinking problems as the fatty substances accumulate in the brain.
The decision rests on a multicenter, randomized, double-blind trial involving 43 patients aged 12 and older who had already stabilized systemic symptoms on enzyme replacement therapy.
Over 52 weeks, participants receiving daily oral venglustat improved on a combined measure of ataxia and cognitive function compared with those who continued intravenous enzyme replacement therapy every two weeks.
Common side effects include gastrointestinal symptoms and mood changes. The prescribing information carries a warning for serious psychiatric risks, including suicidal thoughts and behaviors. Animal studies also flagged potential risks of blurred vision in young patients and fetal harm when the drug is taken during pregnancy.
No other therapy has targeted the neurological manifestations of Gaucher type 3, a rare inherited disorder caused by deficient glucocerebrosidase enzyme activity. The FDA’s approval adds a pharmacological option for a patient population whose neurological decline has remained a major therapeutic challenge.
The FDA’s full prescribing information for Infilbray details the warnings, precautions and monitoring recommendations for clinicians.
FDA approves first drug to treat Neurological Symptoms of Type 3 Gaucher Disease https://t.co/iDkUmisc2k pic.twitter.com/6oOXBCqNSv
Worth a look